Nuveen Asset Management LLC Trims Stake in Surgery Partners, Inc. (NASDAQ:SGRY)

Nuveen Asset Management LLC lessened its holdings in Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) by 18.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 563,554 shares of the company's stock after selling 123,729 shares during the period. Nuveen Asset Management LLC owned about 0.44% of Surgery Partners worth $11,930,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. KBC Group NV increased its stake in Surgery Partners by 66.1% in the 4th quarter. KBC Group NV now owns 3,962 shares of the company's stock valued at $84,000 after buying an additional 1,577 shares during the last quarter. MeadowBrook Investment Advisors LLC increased its stake in shares of Surgery Partners by 16.6% during the 4th quarter. MeadowBrook Investment Advisors LLC now owns 10,280 shares of the company's stock worth $218,000 after purchasing an additional 1,460 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Surgery Partners by 279.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,762 shares of the company's stock worth $228,000 after buying an additional 7,925 shares during the period. Empowered Funds LLC bought a new position in Surgery Partners in the 4th quarter worth approximately $245,000. Finally, KLP Kapitalforvaltning AS bought a new position in Surgery Partners in the 4th quarter worth approximately $273,000.

Insider Activity

In other Surgery Partners news, CFO David T. Doherty sold 6,733 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $24.02, for a total transaction of $161,726.66. Following the completion of the transaction, the chief financial officer now owns 150,868 shares in the company, valued at $3,623,849.36. This trade represents a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Marissa Brittenham sold 3,156 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $24.09, for a total transaction of $76,028.04. Following the transaction, the insider now owns 63,408 shares of the company's stock, valued at $1,527,498.72. This trade represents a 4.74% decrease in their position. The disclosure for this sale can be found here. 2.30% of the stock is owned by corporate insiders.

Surgery Partners Trading Up 4.2%

Shares of SGRY traded up $0.96 during trading hours on Friday, reaching $23.76. 2,232,077 shares of the company traded hands, compared to its average volume of 1,102,808. The company's fifty day moving average price is $22.34 and its two-hundred day moving average price is $22.75. The company has a market capitalization of $3.05 billion, a price-to-earnings ratio of -49.50, a price-to-earnings-growth ratio of 19.21 and a beta of 1.96. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.99. Surgery Partners, Inc. has a 12 month low of $19.50 and a 12 month high of $33.97.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The business had revenue of $776.00 million for the quarter, compared to the consensus estimate of $777.77 million. Surgery Partners had a positive return on equity of 2.85% and a negative net margin of 2.03%. The company's revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 EPS. Equities research analysts predict that Surgery Partners, Inc. will post 0.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SGRY has been the subject of several analyst reports. Macquarie cut their price objective on shares of Surgery Partners from $34.00 to $33.00 and set an "outperform" rating for the company in a report on Tuesday, March 11th. Barclays cut their price target on shares of Surgery Partners from $25.00 to $24.00 and set an "equal weight" rating for the company in a report on Tuesday. Benchmark reaffirmed a "buy" rating and set a $35.00 price objective on shares of Surgery Partners in a report on Monday, April 21st. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $35.00 target price on shares of Surgery Partners in a research report on Tuesday, March 25th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $33.56.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.